These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 19336547)

  • 1. Independent effect of EBV and cigarette smoking on nasopharyngeal carcinoma: a 20-year follow-up study on 9,622 males without family history in Taiwan.
    Hsu WL; Chen JY; Chien YC; Liu MY; You SL; Hsu MM; Yang CS; Chen CJ
    Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1218-26. PubMed ID: 19336547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men.
    Chien YC; Chen JY; Liu MY; Yang HI; Hsu MM; Chen CJ; Yang CS
    N Engl J Med; 2001 Dec; 345(26):1877-82. PubMed ID: 11756578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple risk factors of nasopharyngeal carcinoma: Epstein-Barr virus, malarial infection, cigarette smoking and familial tendency.
    Chen CJ; Liang KY; Chang YS; Wang YF; Hsieh T; Hsu MM; Chen JY; Liu MY
    Anticancer Res; 1990; 10(2B):547-53. PubMed ID: 2161639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of maternal Epstein-Barr virus infection and risk of acute leukemia in the offspring.
    Tedeschi R; Bloigu A; Ogmundsdottir HM; Marus A; Dillner J; dePaoli P; Gudnadottir M; Koskela P; Pukkala E; Lehtinen T; Lehtinen M
    Am J Epidemiol; 2007 Jan; 165(2):134-7. PubMed ID: 17005627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma.
    Twu CW; Wang WY; Liang WM; Jan JS; Jiang RS; Chao J; Jin YT; Lin JC
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):130-7. PubMed ID: 16979842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cigarette smoking increases the risk of nasopharyngeal carcinoma through the elevated level of IgA antibody against Epstein-Barr virus capsid antigen: A mediation analysis.
    Hsu WL; Chien YC; Huang YT; Yu KJ; Ko JY; Lin CY; Tsou YA; Leu YS; Liao LJ; Chang YL; Su JY; Liu Z; Wang CP; Terng SD; Hua CH; Lee JC; Yang TL; Kate Hsiao CH; Wu MS; Tsai MH; Liu MJ; Lou PJ; Hildesheim A; Chen CJ;
    Cancer Med; 2020 Mar; 9(5):1867-1876. PubMed ID: 31925935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic implication of pretreatment titer of serum immunoglobulin A against Epstein-Barr virus capsid antigen in nasopharyngeal carcinoma patients in Sihui, Guangdong.
    Ling W; Cao SM; Huang QH; Li YH; Deng MQ
    Ai Zheng; 2009 Jan; 28(1):57-9. PubMed ID: 19448418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prevalence of immunoglobulin A antibody against Epstein-Barr virus capsid antigen in adult patients with lupus with disease flare: case control studies.
    Chen CJ; Lin KH; Lin SC; Tsai WC; Yen JH; Chang SJ; Lu SN; Liu HW
    J Rheumatol; 2005 Jan; 32(1):44-7. PubMed ID: 15630723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
    Liu MT; Yeh CY
    Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Herbal medicine use, Epstein-Barr virus, and risk of nasopharyngeal carcinoma.
    Hildesheim A; West S; DeVeyra E; De Guzman MF; Jurado A; Jones C; Imai J; Hinuma Y
    Cancer Res; 1992 Jun; 52(11):3048-51. PubMed ID: 1317256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus immune response in high-risk nasopharyngeal carcinoma families in Greenland.
    Friborg J; Jarrett RF; Liu MY; Falk KI; Koch A; Olsen OR; Duncan P; Wohlfarht J; Chen JY; Melbye M
    J Med Virol; 2007 Dec; 79(12):1877-81. PubMed ID: 17935169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.
    Chang KP; Hsu CL; Chang YL; Tsang NM; Chen CK; Lee TJ; Tsao KC; Huang CG; Chang YS; Yu JS; Hao SP
    Oral Oncol; 2008 Aug; 44(8):784-92. PubMed ID: 18206420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups.
    Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ
    Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of patients with positive Epstein-Barr virus serologic status in the absence of nasopharyngeal carcinoma in Hong Kong.
    Lo S; Ho WK; Wei WI
    Arch Otolaryngol Head Neck Surg; 2004 Jun; 130(6):770-2. PubMed ID: 15210561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies to Epstein-Barr virus-specific DNase and DNA polymerase in the chronic fatigue syndrome.
    Jones JF; Williams M; Schooley RT; Robinson C; Glaser R
    Arch Intern Med; 1988 Sep; 148(9):1957-60. PubMed ID: 2843138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serological and immunohistological assessment of Epstein-Barr virus infection in Sicilian patients with suspected nasopharyngeal carcinoma.
    Ammatuna P; de Thè G; Speciale R; Sammartano F; Arista S; Zerillo G
    Microbiologica; 1988 Apr; 11(2):89-94. PubMed ID: 2841559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of risk factors and antibody profiles in epstein-barr virus genome-positive and -negative hodgkin lymphoma.
    Chang ET; Zheng T; Lennette ET; Weir EG; Borowitz M; Mann RB; Spiegelman D; Mueller NE
    J Infect Dis; 2004 Jun; 189(12):2271-81. PubMed ID: 15181575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation.
    Xu FH; Xiong D; Xu YF; Cao SM; Xue WQ; Qin HD; Liu WS; Cao JY; Zhang Y; Feng QS; Chen LZ; Li MZ; Liu ZW; Liu Q; Hong MH; Shugart YY; Zeng YX; Zeng MS; Jia WH
    J Natl Cancer Inst; 2012 Sep; 104(18):1396-410. PubMed ID: 22972969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.